MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose
Data ReadoutnegativeNegative
AI Analysis
Summary
Multiplet Therapeutics stock plunged 73% after a clinical trial failed to meet its primary endpoint on a once-daily dose formulation, resulting in over $1 billion in market capitalization loss.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Trial missed primary endpoint on once-daily dose
Importance:8/10
Sentiment:
-0.95
trial_failurestock_declinemarket_cap_lossclinical_development
Related Companies
Read the original article
Published by yahoo_finance on July 27, 2026 11:08 PM